{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:25:31Z","timestamp":1780788331632,"version":"3.54.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.smim.2022.101618","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T07:25:47Z","timestamp":1656141947000},"page":"101618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls"],"prefix":"10.1016","volume":"59","author":[{"given":"Antonio M.","family":"Risitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Frieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2022.101618_bib1","article-title":"Paroxysmal Nocturnal Hemoglobinuria","volume":"331\u2013374","author":"Risitano","year":"2012"},{"key":"10.1016\/j.smim.2022.101618_bib2","series-title":"Hemolytic Anemias., in Harrison\u2019s Principles of Internal Medicine, 20e.","first-page":"2018","author":"Luzzatto","year":"2018"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/j.1460-2075.1994.tb06240.x","article-title":"Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene","volume":"13","author":"Bessler","year":"1994","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJM199401273300404","article-title":"Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria","volume":"330","author":"Miyata","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0950-3536(89)80010-1","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"2","author":"Rotoli","year":"1989","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.smim.2022.101618_bib7","doi-asserted-by":"crossref","unstructured":"Luzzatto, L. R. Notaro, The \"escape\" model: a versatile mechanism for clonal expansion. Br J Haematol, 2018.","DOI":"10.1111\/bjh.15111"},{"key":"10.1016\/j.smim.2022.101618_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15443","article-title":"Advances in understanding the pathogenesis of acquired aplastic anaemia","author":"Luzzatto","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.smim.2022.101618_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood.V79.6.1400.1400","article-title":"Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes","volume":"79","author":"Mahoney","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1073\/pnas.85.3.880","article-title":"Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells","volume":"85","author":"Stafford","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.smim.2022.101618_bib11","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1073\/pnas.88.9.3762","article-title":"Assembly and deacetylation of N-acetylglucosaminyl-plasmanylinositol in normal and affected paroxysmal nocturnal hemoglobinuria cells","volume":"88","author":"Hirose","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.177.2.517","article-title":"Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria","volume":"177","author":"Takahashi","year":"1993","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.smim.2022.101618_bib13","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1073\/pnas.80.16.5066","article-title":"Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor","volume":"80","author":"Nicholson-Weller","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4049\/jimmunol.129.1.184","article-title":"Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system","volume":"129","author":"Nicholson-Weller","year":"1982","journal-title":"J. Immunol."},{"issue":"7\u201330","key":"10.1016\/j.smim.2022.101618_bib15","article-title":"Decay accelerating factor (CD55)","volume":"178","author":"Nicholson-Weller","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI114172","article-title":"Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.smim.2022.101618_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI114311","article-title":"Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J. Clin. Investig."},{"issue":"25","key":"10.1016\/j.smim.2022.101618_bib18","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.smim.2022.101618_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2011.08690.x","article-title":"Management of paroxysmal nocturnal haemoglobinuria: a personal view","volume":"153","author":"Luzzatto","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.smim.2022.101618_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"de Latour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.smim.2022.101618_bib21","article-title":"How we(\u2019ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future","author":"Risitano","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0890-8508(87)90022-3","article-title":"Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies","volume":"1","author":"Frei","year":"1987","journal-title":"Mol. Cell Probes"},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib23","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.smim.2022.101618_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.smim.2022.101618_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.smim.2022.101618_bib27","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.smim.2022.101618_bib28","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.smim.2022.101618_bib30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"9027","key":"10.1016\/j.smim.2022.101618_bib31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology","volume":"348","author":"Socie","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2022.101618_bib32","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.smim.2022.101618_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.smim.2022.101618_bib34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"Roth","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.smim.2022.101618_bib35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V6.3.270.270","article-title":"Paroxysmal nocturnal hemoglobinuria; a classic description by Paul Strubling in 1882, and a bibliography of the disease","volume":"6","author":"Crosby","year":"1951","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V78.3.820.820","article-title":"Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum","volume":"78","author":"Wilcox","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib38","first-page":"109","article-title":"The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation","volume":"21","author":"Lachmann","year":"1975","journal-title":"Clin. Exp. Immunol."},{"issue":"s3","key":"10.1016\/j.smim.2022.101618_bib39","first-page":"89","article-title":"Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: the bedside and beyond","volume":"92","author":"Risitano","year":"2007","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.smim.2022.101618_bib40","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-017-0496-x","article-title":"Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes","volume":"10","author":"Sica","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"26","key":"10.1016\/j.smim.2022.101618_bib42","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.smim.2022.101618_bib43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","article-title":"Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria","volume":"126","author":"Lin","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.smim.2022.101618_bib44","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1423-0410.2011.01530.x","article-title":"Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test","volume":"102","author":"Hochsmann","year":"2012","journal-title":"Vox Sang."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3324\/haematol.2009.017848","article-title":"Paroxysmal nocturnal hemoglobinuria and eculizumab","volume":"95","author":"Luzzatto","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib48","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.imbio.2012.07.014","article-title":"Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders","volume":"217","author":"Risitano","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.smim.2022.101618_bib49","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-4118-2_10","article-title":"Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies","volume":"735","author":"Risitano","year":"2013","journal-title":"Adv. Exp. Med Biol."},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2013.090001","article-title":"Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Rondelli","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.smim.2022.101618_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.401.401","article-title":"CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)","volume":"128","author":"Sica","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.smim.2022.101618_bib52","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1056\/NEJMc1010351","article-title":"Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab","volume":"363","author":"Risitano","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.hoc.2015.01.009","article-title":"Current and future pharmacologic complement inhibitors","volume":"29","author":"Risitano","year":"2015","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.smim.2016.05.001","article-title":"Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future","volume":"28","author":"Risitano","year":"2016","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.25016","article-title":"Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria","volume":"93","author":"Risitano","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.smim.2022.101618_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib57","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2009-09-244285","article-title":"A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement","volume":"115","author":"Lindorfer","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.smim.2022.101618_bib58","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.4049\/jimmunol.1303131","article-title":"A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors","volume":"192","author":"Paixao-Cavalcante","year":"2014","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2022.101618_bib59","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2022.101618_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-4118-2_9","article-title":"CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation","volume":"735","author":"Holers","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"issue":"17","key":"10.1016\/j.smim.2022.101618_bib61","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.smim.2022.101618_bib62","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.V126.23.2137.2137","article-title":"Safety and pharmacokinetics of the complement inhibitor TT30 in a Phase I Trial for Untreated PNH Patients","volume":"126","author":"Risitano","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib63","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib64","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4049\/jimmunol.157.2.884","article-title":"Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library","volume":"157","author":"Sahu","year":"1996","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib65","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.molimm.2010.10.004","article-title":"Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency","volume":"48","author":"Qu","year":"2011","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.imbio.2012.06.003","article-title":"New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties","volume":"218","author":"Qu","year":"2013","journal-title":"Immunobiology"},{"issue":"6","key":"10.1016\/j.smim.2022.101618_bib67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jmr.972","article-title":"Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin","volume":"22","author":"Magotti","year":"2009","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.smim.2022.101618_bib68","article-title":"From discovery to approval: a brief history of the compstatin family of complement C3 inhibitors","volume":"108785","author":"Mastellos","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.smim.2022.101618_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2022.01.004","article-title":"Compstatins: the dawn of clinical C3-targeted complement inhibition","author":"Lamers","year":"2022","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.smim.2022.101618_bib70","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-78952-1_20","article-title":"Compstatin: a complement inhibitor on its way to clinical application","volume":"632","author":"Ricklin","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"issue":"13","key":"10.1016\/j.smim.2022.101618_bib71","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib72","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.smim.2022.101618_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","article-title":"Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape","volume":"7","author":"Mastellos","year":"2014","journal-title":"Expert Rev. Hematol."},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib74","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.smim.2022.101618_bib75","article-title":"An update on the clinical development of compstatin (AMY-101)","author":"Lambris","year":"2018","journal-title":"11th Int. Conf. Complement Ther."},{"issue":"9","key":"10.1016\/j.smim.2022.101618_bib76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.smim.2022.101618_bib77","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.it.2021.08.001","article-title":"C3-targeted therapy in periodontal disease: moving closer to the clinic","volume":"42","author":"Hajishengallis","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2022.101618_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin. Immunol."},{"issue":"15","key":"10.1016\/j.smim.2022.101618_bib79","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1021\/jm0603419","article-title":"Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin","volume":"49","author":"Katragadda","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.smim.2022.101618_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V122.21.2466.2466","article-title":"Red cell complement loading In PNH patients on eculizumab is associated with a C3 polymorphism which influences C3 function, predicts for increased extravascular hemolysis and provides a rationale For C3 inhibition","volume":"122","author":"Kaudlay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.smim.2022.101618_bib81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.1251.1251","article-title":"APL-2, a complement C3 inhibitor for the potential treatment of paroxysmal nocturnal hemoglobinuria (PNH): phase I data from two completed studies in healthy volunteers","volume":"128","author":"Grossi","year":"2016","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.smim.2022.101618_bib82","article-title":"Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH)","volume":"132","author":"Wong","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib83","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.smim.2022.101618_bib84","unstructured":"A Phase III , Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03500549."},{"issue":"11","key":"10.1016\/j.smim.2022.101618_bib85","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2022.101618_bib86","article-title":"FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT","volume":"2021","author":"Peffault de Latour","year":"2021","journal-title":"Eur. Hematol. Assoc."},{"issue":"S1","key":"10.1016\/j.smim.2022.101618_bib87","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2021-147988","article-title":"Categorized hematologic response to pegcetacoplan and correlations with quality of life in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data From Phase 1b, Phase 2a, and Phase 3 trials","volume":"138","author":"Risitano","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.smim.2022.101618_bib88","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"20","key":"10.1016\/j.smim.2022.101618_bib89","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2021011388","article-title":"Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab","volume":"138","author":"Kulasekararaj","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.smim.2022.101618_bib90","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","article-title":"Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Risitano","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.smim.2022.101618_bib91","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib92","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.17860","article-title":"Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?","volume":"196","author":"Brodsky","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.smim.2022.101618_bib93","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1038\/s41409-021-01372-0","article-title":"Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study","volume":"56","author":"Debureaux","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.smim.2022.101618_bib94","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2022.01.001","article-title":"Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress","author":"Peffault de Latour","year":"2022","journal-title":"Semin. Hematol."},{"issue":"18","key":"10.1016\/j.smim.2022.101618_bib95","first-page":"1724","article-title":"Pegcetacoplan versus Eculizumab in PNH","volume":"385","author":"Kulasekararaj","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.smim.2022.101618_bib96","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMc2106424","article-title":"Pegcetacoplan versus Eculizumab in PNH","volume":"385","author":"Ueda","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"10.1016\/j.smim.2022.101618_bib97","first-page":"1725","article-title":"Pegcetacoplan versus Eculizumab in PNH","volume":"385","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.smim.2022.101618_bib98","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.smim.2022.101618_bib99","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bjh.16711","article-title":"Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies","volume":"191","author":"Peffault de Latour","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.smim.2022.101618_bib100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2019.236877","article-title":"Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Brodsky","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.smim.2022.101618_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V128.22.3891.3891","article-title":"A subcutaneously administered Investigational RNAi Therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: preliminary phase 1\/2 study results in patients with PNH","volume":"128","author":"Hill","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib102","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.166.4.2635","article-title":"Formation of high-affinity C5 convertases of the alternative pathway of complement","volume":"166","author":"Rawal","year":"2001","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.smim.2022.101618_bib103","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.smim.2022.101618_bib104","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.smim.2022.101618_bib105","article-title":"Targeting complement C3 with AMY-101 in COVID-19-associated ARDS: interim results from the ITHACA phase 2 randomized, placebo-controlled trial","author":"Skendros","year":"2021","journal-title":"13th Int. Conf. Complement Ther."},{"issue":"2","key":"10.1016\/j.smim.2022.101618_bib106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"Br. J. Haematol."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:24:07Z","timestamp":1760916247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532322000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":106,"alternative-id":["S1044532322000355"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2022.101618","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2022.101618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101618"}}